Corton Capital Inc. Invests $186,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)

Key Points

• Corton Capital Inc. invested approximately $186,000 in Keros Therapeutics by purchasing 18,212 shares during the first quarter.
• Institutional ownership of Keros Therapeutics stands at 71.56%, with several investors increasing their stakes significantly in recent quarters.
• Keros Therapeutics posted earnings of $3.62 per share for the last quarter, exceeding expectations and marking a substantial improvement from the previous year's loss.

Corton Capital Inc. bought a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 18,212 shares of the company's stock, valued at approximately $186,000.

A number of other institutional investors have also added to or reduced their stakes in the business. Braidwell LP boosted its holdings in shares of Keros Therapeutics by 167.9% in the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after purchasing an additional 1,187,199 shares in the last quarter. Lynx1 Capital Management LP purchased a new position in shares of Keros Therapeutics in the 4th quarter valued at approximately $8,612,000. Millennium Management LLC lifted its stake in shares of Keros Therapeutics by 53.3% in the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company's stock valued at $13,901,000 after purchasing an additional 305,169 shares during the period. Boxer Capital Management LLC purchased a new stake in Keros Therapeutics in the fourth quarter worth about $3,958,000. Finally, Integral Health Asset Management LLC grew its holdings in Keros Therapeutics by 125.0% in the fourth quarter. Integral Health Asset Management LLC now owns 450,000 shares of the company's stock worth $7,124,000 after purchasing an additional 250,000 shares during the period. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Price Performance

Shares of KROS stock traded down $0.20 during trading hours on Thursday, reaching $14.28. 268,137 shares of the company traded hands, compared to its average volume of 1,029,883. Keros Therapeutics, Inc. has a 12-month low of $9.12 and a 12-month high of $72.37. The company has a market cap of $579.85 million, a P/E ratio of -79.27, a P/E/G ratio of 2.62 and a beta of 1.26. The firm has a 50-day moving average price of $14.06 and a 200 day moving average price of $12.65.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a return on equity of 0.75% and a net margin of 1.96%. The company had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. During the same period in the previous year, the firm earned ($1.21) EPS. Sell-side analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Wedbush reiterated a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research note on Friday, May 30th. HC Wainwright reduced their target price on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Scotiabank reduced their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a report on Monday, May 12th. Truist Financial reduced their target price on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Finally, Bank of America lowered Keros Therapeutics from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $30.56.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.